RxDoctor Payments Data

Steven Ballas, MD

Cardiovascular Disease · Warren, OHNPI 1326039447

Payments from drug & device makers

$550in general payments, 2019–2025

Across 16 payments — averaging $34.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Vifor Pharma, Inc.$200
  • Astellas Pharma US Inc$110
  • Amarin Pharma, Inc.$87
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$73
  • Novartis$46
  • Bracco Diagnostics Inc.$22
  • plus $11 from 1 others

What the payments were for

  • Speaking & faculty fees$20036%
  • Food & beverage$24945%
  • Education$10118%

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$550 in reported general payments places this provider in the 30th percentile of 827 cardiovascular disease providers in Ohio.

See all cardiovascular disease providers in Ohio

Medicare billing

Part B allowed, 2024
$173,866
Medicare patients
1,891
Services billed
3,684

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban342$331,847
EntrestoSacubitril/Valsartan162$179,484
JardianceEmpagliflozin89$103,042
XareltoRivaroxaban104$92,985
Repatha SureclickEvolocumab28$22,446
Metoprolol Succinate504$7,492
Repatha SyringeEvolocumab13$6,861
Atorvastatin Calcium250$2,538
Diltiazem 24hr Er (Cd)Diltiazem Hcl28$2,311
Bumetanide67$1,993
Isosorbide Mononitrate ErIsosorbide Mononitrate83$1,554
Rosuvastatin Calcium104$1,488
Ranolazine ErRanolazine28$1,426
Digoxin47$1,210
Carvedilol117$1,145

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$46$179,484162 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 827 cardiovascular disease providers in Ohio.

Other cardiovascular disease in Warren

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →